Suqi Zeng

Suqi Zeng

Auto-generated profile, based on publicly available information

Suqi Zeng

Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, People's Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Digital Health
Verified
Journal Article
Closed access
SZSuqi Zeng
Suqi Zeng
CDChenyu Dong
Chenyu Dong
CLChuan Liu
Chuan Liu
JZJunhai Zhen
Junhai Zhen
YPYu Pu
Yu Pu
WDWeiguo Dong
Weiguo Dong
Aims: This study aimed to evaluate the related research on artificial intelligence (AI) in inflammatory bowel disease (IBD) through bibliometrics analysis and identified the research basis, current hotspots, and future development. Methods: The related literature was acquired from the Web of Science Core Collection (WoSCC) on 31 December 2024. Co-occurrence and cooperation relationship analysis of (cited) authors, institutions, countries, cited journals, references, and keywords in the literature were carried out through CiteSpace 6.1.R6 software and the Online Analysis platform of Literature Metrology. Meanwhile, relevant knowledge maps were drawn, and keywords clustering analysis was performed. Results: According to WoSCC, 1919 authors, 790 research institutions, 184 journals, and 49 countries/regions published 176 AI-related papers in IBD during 1999–2024. The number of papers published has increased significantly since 2019, reaching a maximum by 2023. The United States had the highest number of publications and the closest collaboration with other countries. The clustering analysis showed that the earliest studies focused on “psychometric value” and then moved to “deep learning model,” “intestinal ultrasound,” and “new diagnostic strategies.” Conclusion: This study is the first bibliometric analysis to summarize the current status and to visually reveal the development trends and future research hotspots of the application of AI in IBD. The application of AI in IBD is still in its infancy, and the focus of this field will shift to improving the efficiency of diagnosis and treatment through deep learning techniques, big data-based treatment, and prognosis prediction.

15 July 2026 in Gut Microbes
Verified
Journal Article
Open access
SZSuqi Zeng
Suqi Zeng
SJShanshan Jiang
Shanshan Jiang
JSJianxuan Sun
Jianxuan Sun
YCYan Chen
Yan Chen
MQMeiqi Qiu
Meiqi Qiu
WDWeiguo Dong
Weiguo Dong
Fusobacterium nucleatum (F. nucleatum) has been increasingly implicated in the pathogenesis of inflammatory bowel disease (IBD), yet the mechanisms underlying its effects remain incompletely defined. In this study, we integrated human fecal and mucosal samples, comparative metabolomics, multiple experimental colitis models, bacterial genetic manipulation, macrophage functional assays, and host signaling analyses to identify a macrophage-centered mechanism through which F. nucleatum exacerbates colitis. We show that F. nucleatum colonization increases intestinal and systemic levels of its metabolite succinic acid, upregulates the expression of its cognate receptor SUCNR1 on intestinal macrophages, activates NF-κB signaling, and promotes pro-inflammatory macrophage activation. This macrophage inflammatory response is associated with epithelial barrier disruption, increased epithelial apoptosis, and aggravated mucosal and systemic inflammation. A fumarate reductase-deficient (frdA-KO) F. nucleatum strain with impaired succinic acid production showed a markedly reduced capacity to activate macrophage NF-κB signaling, induce macrophage inflammatory activation, and aggravate colitis, whereas exogenous succinic acid restored these effects in the frdA-KO setting. Moreover, siSUCNR1 and pharmacological NF-κB inhibition substantially attenuated succinic acid-induced macrophage inflammatory activation, supporting the involvement of a SUCNR1-NF-κB signaling cascade. Collectively, these findings demonstrate that F. nucleatum exacerbates colitis by producing succinic acid and engaging SUCNR1-NF-κB-dependent inflammatory activation of macrophages, highlighting the F. nucleatum-succinic acid-SUCNR1-NF-κB axis as a potential therapeutic target in IBD.